tiprankstipranks
Advertisement
Advertisement
Aligos Therapeutics signs license deal to develop pevifoscorvir in China
PremiumThe FlyAligos Therapeutics signs license deal to develop pevifoscorvir in China
2M ago
Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity
Premium
Ratings
Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity
2M ago
Aligos Advances HBV Candidate With Interim Data, Fast Track
Premium
Company Announcements
Aligos Advances HBV Candidate With Interim Data, Fast Track
2M ago
ALGS Earnings this Week: How Will it Perform?
PremiumPre-EarningsALGS Earnings this Week: How Will it Perform?
3M ago
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play
Premium
Company Announcements
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play
3M ago
Aligos announces data from two presentations at CROI on pevifoscorvir sodium
Premium
The Fly
Aligos announces data from two presentations at CROI on pevifoscorvir sodium
4M ago
Aligos Therapeutics management to meet virtually with Piper Sandler
PremiumThe FlyAligos Therapeutics management to meet virtually with Piper Sandler
5M ago
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
Premium
Company Announcements
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
5M ago
Aligos Therapeutics appoints James Hassard as EVP, CCO
Premium
The Fly
Aligos Therapeutics appoints James Hassard as EVP, CCO
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100